Risk of map‐like redness development after eradication therapy for Helicobacter pylori infection
Helicobacter · 2024
DOI: 10.1111/hel.13046 ↗Kurz gefasst
Fachartikel in der Zeitschrift Helicobacter, 2024. Verfasst von Sho Matsumoto und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Helicobacter Infections, Gastritis, Helicobacter pylori. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Map‐like redness is a newly identified endoscopic risk factor for gastric cancer in patients who received Helicobacter pylori eradication therapy. However, the incidence rate of map‐like redness in patients who received eradication, and the risk factors for the development of map‐like redness remain unclear. We hence aimed to investigate the incidence rate of map‐like redness at 1‐year post H. pylori eradication, and evaluated its associations with map‐like redness and gastric cancer in relation with gastric condition. Materials and Methods Endoscopic severity of gastritis and map‐like redness were retrospectively evaluated according to the Kyoto Classification of Gastritis in patients who had undergone endoscopy before and after H. pylori eradication therapy.
Results
The incidence rate of map‐like redness for all 328 patients at a mean of 1.2 ± 0.6 years after eradication was 25.3% (95% confidence interval [CI]: 20.7%–30.4%). Patients who developed map‐like redness were older, had more severe atrophy and intestinal metaplasia, a higher total score of the Kyoto Classification of Gastritis both before and after eradication, and a higher rate of gastric cancer history than patients who did not have map‐like redness. On multivariate analysis, risk of map‐like redness was increased in patients with intestinal metaplasia (odds ratio [OR]: 2.794, 95% CI: 1.155–6.757) and taking acid inhibitors (OR: 1.948, 95% CI: 1.070–3.547). Characteristics of H. pylori ‐positive patients with gastric cancer history were patients who were older (OR: 1.033, 95% CI: 1.001–1.066), taking acid inhibitors (OR: 4.456, 95% CI: 2.340–8.484), and with occurrence of map‐like redness after eradication therapy (OR: 2.432, 95% CI: 1.264–4.679).
Conclusions
Map‐like redness is observed in one fourth of patients at 1‐year post eradication. Patients who developed map‐like redness were found to have severe intestinal metaplasia and taking acid inhibitors, and hence such patients require increased attention at surveillance endoscopy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Tokyo Medical University Hospital, Tokyo, Japan.
- Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital, Tokyo, Japan.
- Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
ORCID-Profile: Mitsushige Sugimoto, Eri Iwata
Zitieren
APA
Matsumoto, S., Sugimoto, M., Fukuzawa, M., Uesugi, N., Iwata, E., Kagawa, Y., Madarame, A., Koyama, Y., Morise, T., Uchida, K., Yamaguchi, H., Kono, S., Naito, S., Kawai, T., & Itoi, T. (2024). Risk of map‐like redness development after eradication therapy for Helicobacter pylori infection. Helicobacter. https://doi.org/10.1111/hel.13046
Vancouver
Matsumoto S, Sugimoto M, Fukuzawa M, Uesugi N, Iwata E, Kagawa Y, et al. Risk of map‐like redness development after eradication therapy for Helicobacter pylori infection. Helicobacter. 2024. doi:10.1111/hel.13046
BibTeX
@article{Matsumoto2024,
author = {Matsumoto, Sho and Sugimoto, Mitsushige and Fukuzawa, Masakatsu and Uesugi, Nana and Iwata, Eri and Kagawa, Yasuyuki and Madarame, Akira and Koyama, Yohei and Morise, Takashi and Uchida, Kumiko and Yamaguchi, Hayato and Kono, Shin and Naito, Sakiko and Kawai, Takashi and Itoi, Takao},
title = {Risk of map‐like redness development after eradication therapy for Helicobacter pylori infection},
journal = {Helicobacter},
year = {2024},
doi = {10.1111/hel.13046}
}
EUVIMED